Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
galmedpharma.investorroom.com
Company Research
Source: PR Newswire
Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects.Galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity lineTEL AVIV, Israel, Sept. 19, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for fibroinflammatory indications announced today that based on the recently published results from the Open-Label part of its Phase 3 NASH study, new scientific publications on the role of SCD1 as a critical metabolic signaling hub as well as an extended cash runway, it plans to broaden its drug development activities. The planned expansion consists of two additional programs over the next two years. One program aims to identify novel Aramchol-based drug combinations to overcome resistance to s
Show less
Read more
Impact Snapshot
Event Time:
GLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLMD alerts
High impacting Galmed Pharmaceuticals Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GLMD
News
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
GLMD
Sec Filings
- 2/18/25 - Form SCHEDULE
- 1/7/25 - Form S-8
- GLMD's page on the SEC website